Company profile
UK company 11119959, incorporated on 20 December 2017.
Amphista Therapeutics Developing novel medicines through next generation protein degradation
Amphista Therapeutics Limited is a UK company with status active founded in 2017 based in East of England.
Company number 11119959
Reference milestones and recent Companies House filing stream events.
RESOLUTIONS | Transaction WUY4R0JPUVdhZGlxemtjeA | Paper/PDF filed
Published 25 Aug 2026 23:06
MA | Transaction MzUzODcyNzAwOWFkaXF6a2N4 | Paper/PDF filed
Published 25 Aug 2026 23:03
Company registered at Companies House
Amphista Therapeutics develops pharmaceuticals that are designed to use targeted protein degradation to hijack and suppress cell's responsible for disease progression.
Amphista is a biotech company based around PROTAC technology. Proteolysis targeting chimeras (PROTACs) are an alternative to traditional small molecules as a therapeutic approach to inhibiting disease causing proteins.
Amphista Therapeutics is a University of Dundee spin off company that is developing targeted protein degradation platforms
The company was incorporated in December 2017 with investment from Advent Life Sciences
commercial in confidence
